1. Anti-infection
  2. HCV
    HBV
  3. Inarigivir soproxil

Inarigivir soproxil (Synonyms: SB9200; GS-9992)

目录号: HY-109035 纯度: 99.55%
产品使用指南

Inarigivir soproxil (SB9200) 是一种先天免疫激动剂,对耐药 HCV 变异体具有有效的抗病毒活性,在基因型 1 HCV 复制子系统的细胞中,对 HCV 1a/1bEC50 分别为 2.2 和 1.0 μM。Inarigivir soproxil 是 SB 9000 的口服生物可利用前药。Inarigivir soproxil 对 RNA 病毒具有广谱抗病毒活性,包括 HCV、诺如病毒、呼吸道合胞病毒以及流感和 HBV

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Inarigivir soproxil Chemical Structure

Inarigivir soproxil Chemical Structure

CAS No. : 942123-43-5

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥6966
In-stock
5 mg ¥4500
In-stock
10 mg ¥7100
In-stock
25 mg ¥13000
In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Customer Review

注册 MCE会员完成审核
即刻享有 积分商城 300 专属积分

Top Publications Citing Use of Products
  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable prodrug of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV[1][2].

IC50 & Target

EC50: 2.2/1.0 μM (HCV 1a/1b)[1].

体外研究
(In Vitro)

Inarigivir soproxil (SB 9200) is a first-in-class oral modulator of innate immunity that acts via the activation of the RIG-I and NOD2 pathways[1].
Inarigivir soproxil is an effective inhibitor of HCV replication in cell culture. The antiviral activity of Inarigivir soproxil against HCV was assessed using genotype 1 HCV replicon systems in duplicate experiments using 4 drug concentrations. Inarigivir soproxil inhibits HCV replication with EC50s of 2.2 and 1.0 µM, and EC90s of 8.0 and 6.0 µM for genotype 1A and 1B, respectively[1].
Inarigivir soproxil (SB 9200), an orally bioavailable dinucleotide, activates the viral sensor proteins, retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) causing the induction of the interferon (IFN) signaling cascade for antiviral defense[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

The induction of host immune responses by pretreatment with Inarigivir soproxil (SB 9200) followed by Entecavir (ETV) resulted in antiviral efficacy that was superior to that obtained using the strategy of viral reduction with ETV followed by immunomodulation[2].
Sequential treatment of chronic WHV carrier woodchucks with Inarigivir soproxil (30 mg/kg)followed by ETV induced marked suppression of serum viremia and antigenemia and delayed recrudescence of viral replication compared to sequential treatment with ETV followed by Inarigivir soproxil[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Woodchucks chronically infected with woodchuck hepatitis virus (WHV)[2]
Dosage: 30 mg/kg
Administration: Orally treated once daily; group 1 received ETV for 4 weeks followed by Inarigivir soproxil for 12 weeks. Group 2 received Inarigivir soproxil for 12 weeks followed by ETV for 4 weeks
Result: Both groups demonstrated marked reductions in hepatic WHV nucleic acid levels which were more pronounced in Group 2.
Clinical Trial
分子量

703.62

Formula

C25H34N7O13PS

CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

溶解性数据
In Vitro: 

DMSO : 80 mg/mL (113.70 mM; Need ultrasonic)

H2O : 10 mg/mL (14.21 mM; ultrasonic and warming and heat to 60°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.4212 mL 7.1061 mL 14.2122 mL
5 mM 0.2842 mL 1.4212 mL 2.8424 mL
10 mM 0.1421 mL 0.7106 mL 1.4212 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 5 mg/mL (7.11 mM); Clear solution

    此方案可获得 ≥ 5 mg/mL (7.11 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

  • 2.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 4 mg/mL (5.68 mM); Clear solution

    此方案可获得 ≥ 4 mg/mL (5.68 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 40.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 4 mg/mL (5.68 mM); Clear solution

    此方案可获得 ≥ 4 mg/mL (5.68 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 40.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 4.

    请依序添加每种溶剂: 5% DMSO    40% PEG300    5% Tween-80    50% saline

    Solubility: ≥ 2.5 mg/mL (3.55 mM); Clear solution

*以上所有助溶剂都可在 MCE 网站选购。
参考文献

纯度: 99.55%

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Inarigivir soproxil
目录号:
HY-109035
需求量: